ABCURO, INC.
Monoclonal antibodies targeting an inhibitory T cell receptor for immune checkpoint blockade in melanoma
- Sector
- Biotech
- Headquarters
- NEWTON, MA
- Founded
- 2015
- Latest Form D
- $39.4M, Aug 2026
- Total capital
- $258M
- Federal grants
- $295K
- 2 awards · 2019–2020
- Rank in peer group#91 of 392
- Private capital raised
- $257M
- 6 Form D · last Aug 2026
- 2 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 2
- 21 pending · first 2021
- Rank in peer group#53 of 392
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 6th filing$39.4M
- Private capital raisedForm D · SEC · 5th filing$80M
- Private capital raisedForm D · SEC · 4th filing$120M
- Federal grantHealth and Human S · Phase I · Antibody blockade of T cell activating co-inhibitory receptor KLRG1 for treatment of melanoma$37K
- Private capital raisedForm D · SEC · 3rd filing$7.6M
- Federal grantHealth and Human S · Phase I · Antibody blockade of T cell activating co-inhibitory receptor KLRG1 for treatment of melanoma$258K
- Private capital raisedForm D · SEC · 2nd filing$8M
- Private capital raisedForm D · SEC · 1st filing$2.3M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#91 · top 23%
- Granted patents#53 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Stefano GullaResearcherExecutive Officer, DirectorLinked by $295K in grants as PI
- Daniel MansuriDirectorNamed in SEC Form D filings
- Darlene Alexander Deptula-HicksDirectorNamed in SEC Form D filings
- David de GraafExecutive Officer, DirectorNamed in SEC Form D filings
- Donald McCarthyDirectorNamed in SEC Form D filings
- Evan ThompsonExecutive OfficerNamed in SEC Form D filings
Show all 24 people
- Iyona RajkomarDirectorNamed in SEC Form D filings
- Jason HaflerDirectorNamed in SEC Form D filings
- John EdwardsDirectorNamed in SEC Form D filings
- John Alexander MartinExecutive Officer, DirectorNamed in SEC Form D filings
- Julius Evan KnowlesDirectorNamed in SEC Form D filings
- K. Evan ThompsonExecutive Officer, DirectorNamed in SEC Form D filings
- Mark Alexander PruzanskiDirectorNamed in SEC Form D filings
- Michael Alexander DybbsDirectorNamed in SEC Form D filings
- Michele Alexander ParkDirectorNamed in SEC Form D filings
- Ming Alexander FangDirectorNamed in SEC Form D filings
- Nalan Evan UtkuDirectorNamed in SEC Form D filings
- Rajeev Alexander ShahDirectorNamed in SEC Form D filings
- Richard Alexander MotschwillerExecutive OfficerNamed in SEC Form D filings
- Robert Evan MillmanDirectorNamed in SEC Form D filings
- Ryan BerryDirectorNamed in SEC Form D filings
- Sarah Alexander BoyceDirectorNamed in SEC Form D filings
- Tomer Alexander KarivDirectorNamed in SEC Form D filings
- Yajun Evan XuDirectorNamed in SEC Form D filings
What it has protected
USPTO · 2 granted of 23- PendingKiller Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesUSPTOApplication 18291013
- PendingMethods Of Treating Disorders Associated With Excess Or Unwanted Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Expressing T Cells With KLRG1 Depleting AntibodiesUSPTOApplication 18883109
- GrantedMethods Of Treating Disorders Associated With Excess Or Unwanted Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Expressing T Cells With KLRG1 Depleting AntibodiesUSPTOUS 12,139,541
Show all 23 patent records
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesMar 27, 2025 · Application 18291013Pending
- Methods Of Treating Disorders Associated With Excess Or Unwanted Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Expressing T Cells With KLRG1 Depleting AntibodiesMar 27, 2025 · Application 18883109Pending
- Methods Of Treating Disorders Associated With Excess Or Unwanted Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Expressing T Cells With KLRG1 Depleting AntibodiesNov 12, 2024 · US 12,139,541Granted
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesNov 23, 2021 · US 11,180,561Granted
- Methods Of Treating T-cell Large Granular Lymphocytic LeukemiaApplication 63699857Pending
- Methods Of Treating Inclusion Body Myositis (ibm)Application 63617063Pending
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesApplication PCTUS2022038310Pending
- ANTI-KLRG1 AntibodiesApplication PCTUS2022021945Pending
- ANTI-KLRG1 AntibodiesApplication PCTUS2022021972Pending
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesApplication 63308222Pending
- ANTI-KLRG1 AntibodiesApplication 63294436Pending
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesApplication 63225828Pending
- ANTI-KLRG1 AntibodiesApplication 63166678Pending
- ANTI-KLRG1 AntibodiesApplication 63166663Pending
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesApplication PCTUS2020027498Pending
- ANTI-KLRG1 AntibodiesApplication PCTUS2019050110Pending
- Killer Cell Lectin-like Receptor Subfamily G Member 1 (KLRG1) Depleting AntibodiesApplication 62831713Pending
- ANTI-KLRG1 AntibodiesApplication 62732329Pending
- Methods Of Treating T-cell Large Granular Lymphocytic LeukemiaApplication PCTUS2025048228Pending
- Methods Of Treating Inclusion Body Myositis (ibm)Application 19603099Pending
- Methods Of Treating T-cell Large Granular Lymphocytic LeukemiaApplication 63857285Pending
- Methods Of Treating Inclusion Body Myositis (ibm)Application PCTUS2025010129Pending
- Methods Of Treating Inclusion Body Myositis (ibm)Application 63707402Pending
Related companies, and why
- Vesalius TherapeuticsSimilar federal contract value in Biotech · null in contracts
- MIMIVAX VARIA VENTURES LLCSimilar federal contract value in Biotech · null in contracts
- PARMEDICS, INCSimilar federal contract value in Biotech · null in contracts
- CODOMAX INC.Similar federal contract value in Biotech · null in contracts
- Stem Biotech LLCSimilar federal contract value in Biotech · null in contracts
- BeneFix, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .